The Weight of CRO Selection

For an emerging biopharma/biotech, the decision of which CRO you select carries a weight it doesn’t at a large pharma. You likely have one shot at the program, a small team, and a runway that doesn’t forgive a misstep. How you select a partner matters as much as which partner you select.

Many sponsors still treat this activity as procurement, but it's worth it to turn a one-time activity into a strategic capability — building the muscle to choose well, again and again, not just once.

Four moves you can make:

1. Consider your trial before you write the RFP. Rare disease across nine countries is a different trial than a 4,000-patient Phase III cardiometabolic study, yet both often go to RFP stage under the same boilerplate scope. Define therapeutic area, population, endpoints, regulatory pathway, and your own oversight appetite first.

2. Align the outsourcing model to your actual maturity. Full-service feels like relief, but if you’ve never managed a CRO at scale, you risk outsourcing the very oversight you need to govern it. FSP promises control, but only if you have the integration muscle. The model follows the strategy and your internal capabilities.

3. Look past cost. The cheapest bid usually becomes the most expensive trial. Weight therapeutic depth, RBQM maturity (ICH E6(R3) is a culture, not a checkbox), named committed functional leads, financial stability, and how the CRO behaves when a milestone slips.

4. Combine market data with experiential evidence. Bid benchmarks and analyst reporting show what’s generally true. Reference calls, site feedback, and prior engagement KPIs show what’s true for you.

One good selection runs a trial for a biotech. The compounding framework — the scorecard, the benchmarks, the relationship architecture — becomes a capability your organization carries forward. This is the part sponsors usually reach for too late — after the cheapest bid has already become the most expensive trial. It’s the work I do with emerging biotech:  building the framework before the choice, not after.

Emerging sponsors rarely get a second attempt at this decision. CRO selection and oversight exists for that reason.